Last reviewed · How we verify
Advate®
At a glance
| Generic name | Advate® |
|---|---|
| Also known as | octocog alfa, Antihemophilic Factor [Recombinant] Plasma/Albumin Free Method, Recombinant Human Coagulation Factor VIII for injection, rAHF-PFM, Antihemophilic Factor (Recombinant) |
| Sponsor | Bioverativ Therapeutics Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A (PHASE1)
- An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.
- Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) (PHASE4)
- Register of Patients With haEmophilia A tReated With Afstyla®
- A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD (PHASE3)
- Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor (PHASE4)
- rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |